1341 PharmaBio Delegate Booklet

1341 PharmaBio Delegate Booklet 28/11/07 14:41 Page 12
Speakers
Mr Christian Siebert
DG Enterprise and Industry
European Commission
Christian Siebert is Head of Unit in the European Commission, Enterprise and
Industry Directorate-General, Unit “Competitiveness in the Pharmaceutical
Industry and Biotechnology”. The activity of the unit includes the
Pharmaceutical Forum, a follow-up to the “G10 Medicines” group’s policy
recommendations on access of patients to medicines and on improved
conditions for innovation in the European pharmaceuticals industry. The unit
also contributes to the development/implementation of the European
Commissions’ policy document and action plan “Life Sciences and
Biotechnology – a Strategy for Europe”.
He joined the European Commission in 1991 and held previous positions in the
Enterprise/Industry Department, dealing with biotechnology, the food
industry, co-operation with Central/Eastern Europe and with GATT/WTO
matters. He also has been Assistant to the Director-General for Industry.
Mr Siebert graduated (M.A.) in Political Science and Economics at the
University of Mainz (Germany), before completing post-graduate studies at
the College of Europe (Bruges, Belgium).
Mr Shinichi Tamura
Chief Executive Officer
Sosei Group Corporation
Mr Tamura is co-founder of Sosei Company Limited and has been its Chief
Executive Officer since 1990, and since October 2006 Chief Executive Officer of
Sosei Group Corporation. From 1988 to 1991, Mr Tamura was the Representative
Director (Chief Executive Officer) for Genentech Ltd and was in charge of the
Japanese operations for Genentech Inc. From 1986, he had been advisor for
Genentech, IDEC, Geron and Kissei, among others, for various periods of time.
Prior to that, he has held various positions in Planning and Development at
Fujisawa (Astellas) from 1978 to 1986. Mr Tamura has an MS in Biochemistry
from the University of Tokyo, in addition to studying Cultural Anthropology.
Mr Brian Thornley
Chief Operations Officer
Aegate
Brian Thornley joined Aegate in August 2007 as Chief Operations Officer,
bringing with him many years experience in the pharmaceutical industry.
Previously, Mr Thornley was Director of European Supply Chain for GSK where
he was responsible for managing the supply chain from 25 factories across 44
countries in Europe. At GSK, he was also responsible for supporting European
sales of £4.2Bn.
Mr Thornley is an active member of the European Federation of
Pharmaceutical Industry and Associations (EFPIA)’s Distribution and Supply
Chain Committee.
–– 12 ––
Mr Robert Wessman
President and Chief Executive Officer
Actavis Group
Robert Wessman joined the board in April 2007. He has been the President
and Chief Executive Officer of Actavis since 2002, following the merger with
Delta, where he had served as Chief Executive Officer since 1999. Under Mr
Wessman’s leadership, Actavis has experienced phenomenal growth, from
being a small domestic company in Iceland to becoming one of the largest
companies in the generics industry. A business administration graduate and
lecturer at the University of Iceland, he worked previously at Icelandic
transportation company Samskip, advancing to the post of Chief Executive
Officer in Germany. Mr Wessman is also a Board member of the Iceland
Chamber of Commerce.
Mr Dan Zabrowski
Global Head Pharma Partnering
Roche
Dan Zabrowski is the Global Head of Pharma Partnering. In this role, Dr
Zabrowski oversees Roche’s world class network of strategic alliances with
biotech companies and creates new alliances for the future. From 2002 to
2007, Dr Zabrowski served as the Global Head of Pharma Development
Operations and Vice President of Pharma Development, Nutley for Hoffmann-
La Roche, Inc. This group is responsible for management of all global clinical
trials for Roche.
Prior to this assignment, Dr Zabrowski was Global Head, Drug Regulatory
Affairs for Roche Pharma Division for 5 years. Dr Zabrowski joined Roche in
1995 following the company’s acquisition of Syntex, Inc, where he held a
variety of positions in Regulatory Affairs. Prior to that assignment, he led
Regulatory Affairs in North America for Fujisawa Pharmaceutical Company. Dr
Zabrowski started his regulatory career at Searle. Before moving to the
regulatory field, Dr Zabrowski conducted drug discovery research at Searle in
serotonin receptor modulators.
Dr Zabrowski received a BA degree in Chemistry from Saint Louis University
and a PhD in Organic Chemistry from Indiana University – Bloomington.